Literature DB >> 18632827

Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.

Yuka Yamamoto1, Yoshihiro Nishiyama, Reiko Kameyama, Keiichi Okano, Hirotaka Kashiwagi, Akihiro Deguchi, Masato Kaji, Motoomi Ohkawa.   

Abstract

UNLABELLED: The purpose of this study was to retrospectively investigate the feasibility of 11C-choline PET, compared with 18F-FDG PET, for the detection of hepatocellular carcinoma (HCC).
METHODS: A total of 16 HCC lesions in 12 patients were examined with both 11C-choline PET and 18F-FDG PET. Tumor lesions were identified as areas of focally increased uptake, exceeding that of surrounding noncancerous liver tissue. For semiquantitative analysis, the tumor-to-liver (T/L) ratio was calculated by dividing the maximal standardized uptake value (SUV) in HCC lesions by the mean SUV in noncancerous liver tissue.
RESULTS: 11C-choline PET showed a slightly higher detection rate than did 18F-FDG PET for detection of HCC (63% vs. 50%, respectively), although this difference was not statistically significant. 11C-choline PET had a better detection rate for moderately differentiated HCC lesions but not for those poorly differentiated (75% vs. 25%, respectively). In contrast, 18F-FDG PET exhibited the opposite behavior, with corresponding detection rates of 42% and 75%, respectively. The mean 11C-choline SUV and T/L ratio in moderately differentiated HCC lesions were higher than those in poorly differentiated HCC lesions. In contrast, the mean 18F-FDG SUV and T/L ratio in poorly differentiated HCC were higher than those in moderately differentiated HCC. These differences, however, were also not statistically significant.
CONCLUSION: 11C-choline PET had a better detection rate for moderately differentiated HCC lesions but not for poorly differentiated HCC lesions, whereas 18F-FDG PET produced the opposite result. 11C-choline is a potential tracer to complement 18F-FDG in detection of HCC lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632827     DOI: 10.2967/jnumed.108.052639

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  Quantitative liver lesion volume determination by nanoparticle-based SPECT.

Authors:  Dániel S Veres; Domokos Máthé; Ildikó Futó; Ildikó Horváth; Akos Balázs; Kinga Karlinger; Krisztián Szigeti
Journal:  Mol Imaging Biol       Date:  2014-04       Impact factor: 3.488

2.  18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

3.  An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Wenjie Miao; Pei Nie; Guangjie Yang; Yangyang Wang; Lei Yan; Yujun Zhao; Ting Yu; Mingming Yu; Fengyu Wu; Wei Rao; Zhenguang Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-04       Impact factor: 9.236

Review 4.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

Review 5.  Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma.

Authors:  Jason Wachsmann; Fangyu Peng
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

7.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

8.  PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline.

Authors:  Jeffrey A Kolthammer; David J Corn; Nathan Tenley; Chunying Wu; Haibin Tian; Yanming Wang; Zhenghong Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-23       Impact factor: 9.236

9.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

Review 10.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.